Cantor Fitzgerald Positive on Valeant (VRX) Amid Vyzulta Approval

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $23 price target on Valeant Pharmaceuticals (NYSE: VRX) saying she sees some good opportunity with the FDA approval of Vyzulta.

"We think this could be a blockbuster drug for VRX, and the Street was not expecting approval until 2018+ given the CRL VRX received for the drug this summer," Chen said.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $11.93 yesterday.

You May Also Be Interested In

• Cantor Fitzgerald Starts Milestone Pharmaceuticals (MIST) at Overweight
• Apple Hospitality REIT (APLE) Reiterated at Overweight by Cantor Fitzgerald: Set up for Growth
• Harrow study shows Iheezo cuts discomfort after eye injections